Anebulo Pharmaceuticals Inc

NASDAQ ANEB

Download Data

Anebulo Pharmaceuticals Inc Non-current Liabilities to Total Liabilities Ratio 5 year CAGR for the Trailing 12 Months (TTM) ending March 31, 2024

Anebulo Pharmaceuticals Inc Non-current Liabilities to Total Liabilities Ratio 5 year CAGR is NA for the Trailing 12 Months (TTM) ending March 31, 2024. The total non-current liabilities to total liabilities ratio measures the proportion of a company's non-current liabilities to its total liabilities. It is calculated by dividing the total non-current liabilities by the total liabilities. This ratio provides insights into the composition of a company's liabilities and the extent to which it relies on long-term debt and obligations. A higher ratio indicates a greater reliance on non-current liabilities, suggesting potential long-term financial commitments and increased financial risk. CAGR, or the Compound Annual Growth Rate, quantifies the mean annual growth rate of an investment or financial metric over a specified time span, considering the influence of compounding. It is instrumental in determining the true annualized return on an investment.
  • Anebulo Pharmaceuticals Inc Non-current Liabilities to Total Liabilities Ratio for the Trailing 12 Months (TTM) ending March 31, 2023 was 0.66, a -15.35% change year over year.
  • Anebulo Pharmaceuticals Inc Non-current Liabilities to Total Liabilities Ratio for the Trailing 12 Months (TTM) ending March 31, 2022 was 0.77, a -17.25% change year over year.
  • Anebulo Pharmaceuticals Inc Non-current Liabilities to Total Liabilities Ratio for the Trailing 12 Months (TTM) ending March 31, 2021 was 0.94.
NASDAQ: ANEB

Anebulo Pharmaceuticals Inc

CEO Dr. Joseph F. Lawler M.D., Ph.D.
IPO Date May 7, 2021
Location United States
Headquarters 1415 Ranch Road 620 South, Lakeway, TX, United States, 78734
Employees 2
Sector Healthcare
Industry Biotechnology
Description

Anebulo Pharmaceuticals, Inc., a clinical-stage biotechnology company, engages in developing solutions for people suffering from acute cannabinoid intoxication (ACI) and substance addiction. The company's lead product candidate is ANEB-001, a small molecule cannabinoid receptor antagonist, which is in a Phase II clinical trial to address the unmet medical need for a specific antidote for ACI. Anebulo Pharmaceuticals, Inc. was incorporated in 2020 and is based in Lakeway, Texas.

Similar companies

ADAG

Adagene Inc

NA

NA

ACRV

Acrivon Therapeutics Inc. Common Stock

NA

NA

AVTE

Aerovate Therapeutics Inc

NA

NA

ANTX

AN2 Therapeutics Inc

NA

NA

StockViz Staff

September 20, 2024

Any question? Send us an email